Expanded Access Banner image

Expanded Access

Our mission is to translate scientific advances into new treatments for people with Amyotrophic Lateral Sclerosis (ALS) and Motor Neuron Disease (MND) as rapidly as possible. In addition to conducting clinical trials, NEALS is committed to sharing information about Expanded Access to investigational therapies.

Neals logo
What is Expanded Access

Providing Access to Individuals Who Do Not Qualify for Trials

Expanded Access (EA) is a pathway for people living with a serious and life-threatening disease to access an investigational product that is not yet approved by the FDA. An investigational product offered through EA is experimental, so its effectiveness as a treatment for ALS is not yet known. EA should not interfere with the completion of clinical trials; therefore, EA is meant to be an option for individuals who do not qualify for participation in a clinical trial.

Considerations for Clinicians

Accessing Investigational Products Outside of a Trial

Here you can read an article that describes Expanded Access Programs, compares them to other pathways for accessing investigational treatments, describes some of the challenges at the sponsor and site level, and lists resources that can help overcome these challenges.

A Step by Step Guide

Navigating Expanded Access

Here you can see a roadmap and step by step guide to opening an Expanded Access Program at a site. The CTSA-based program focused on Transforming Expanded Access to Maximize Support and Study (TEAMSS) has assembled each of the critical steps to utilize this mechanism.

Active Expanded Access Protocols

Below is a list of some of the active Expanded Access Protocols. Please note that each protocol has its own list of inclusion and exclusion criteria and not every person living with ALS will qualify. If you have information about an Expanded Access Protocol not listed below, please contact Christina Smith, NEALS Communications Coordinator, at email hidden; JavaScript is required.

Drug/Intervention Location Contacts Website
Pridopidine EAP2 Massachusetts General Hospital
Boston, MA 02114
United States
Anat Weiss Sadan, email hidden; JavaScript is required, 617-726-3015 Visit Site
CNMAu8.EAP02 Multicenter Austin Rynders or Jeremy Evan, 801-676-9695, email hidden; JavaScript is required Visit Site
RAPA-501 Multicenter Daniel H Fowler; Chief Medical Officer, M.D. email hidden; JavaScript is required 301-518-3104 Visit Site

The information is provided “as is.” NEALS shares information concerning Expanded Access as a public service, for general information purposes only. The information is gathered from other public websites and is made available without evaluation or endorsement by NEALS. It may be incomplete, outdated, or irrelevant to a particular reader’s situation. By providing this information, NEALS is not recommending any treatment to individual patients.